Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva® Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS). “Approval to sell LuViva in Mexico is a significant...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the...
The LuViva® Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that Gene Cartwright, the Company’s CEO, will be a featured presenter at...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the 3rd Annual Marcum MicroCap...
The LuViva® Advanced Cervical Scan identified 100% of all cervical disease cases in a blinded clinical study presented at the International Federation for Cervical Pathology and Colposcopy (IFCPC) meeting in London on May 27, 2014. LuViva also correctly identified 44%...
